- Home
- KREF vs PRME Comparison
KREF vs PRME Comparison
Compare KREF & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KREF
- PRME
- Stock Information
- Founded
- KREF 2014
- PRME 2019
- Country
- KREF United States
- PRME United States
- Employees
- KREF N/A
- PRME N/A
- Industry
- KREF Real Estate Investment Trusts
- PRME Medicinal Chemicals and Botanical Products
- Sector
- KREF Real Estate
- PRME Health Care
- Exchange
- KREF Nasdaq
- PRME Nasdaq
- Market Cap
- KREF 606.8M
- PRME 624.0M
- IPO Year
- KREF 2017
- PRME 2022
- Fundamental
- Price
- KREF $9.53
- PRME $3.55
- Analyst Decision
- KREF Buy
- PRME Buy
- Analyst Count
- KREF 7
- PRME 6
- Target Price
- KREF $12.32
- PRME $8.88
- AVG Volume (30 Days)
- KREF 533.5K
- PRME 4.0M
- Earning Date
- KREF 10-20-2025
- PRME 08-07-2025
- Dividend Yield
- KREF 10.55%
- PRME N/A
- EPS Growth
- KREF N/A
- PRME N/A
- EPS
- KREF N/A
- PRME N/A
- Revenue
- KREF $40,393,000.00
- PRME $4,961,000.00
- Revenue This Year
- KREF $27.61
- PRME $126.92
- Revenue Next Year
- KREF N/A
- PRME $87.32
- P/E Ratio
- KREF N/A
- PRME N/A
- Revenue Growth
- KREF N/A
- PRME 739.42
- 52 Week Low
- KREF $8.28
- PRME $1.11
- 52 Week High
- KREF $12.95
- PRME $5.17
- Technical
- Relative Strength Index (RSI)
- KREF 59.50
- PRME 48.57
- Support Level
- KREF $9.10
- PRME $3.09
- Resistance Level
- KREF $9.38
- PRME $3.88
- Average True Range (ATR)
- KREF 0.16
- PRME 0.31
- MACD
- KREF 0.02
- PRME -0.09
- Stochastic Oscillator
- KREF 98.17
- PRME 32.96
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.